Massive trial aims to find optimal Pre-Surgery combo for esophageal cancer
NCT ID NCT04821843
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This large phase 3 study is testing different combinations of chemotherapy, radiation, immunotherapy, and targeted drugs given before surgery for esophageal cancer. The goal is to find which approach works best to improve survival. The trial will enroll 2,000 adults with stage I to IVa esophageal or esophagogastric junction cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Platinum-based chemotherapy, paclitaxel-based chemotherapy, 5-FU analog chemotherapy, immunotherapy (anti-PD-1/PD-L1 antibody), nimotuzumab, radiotherapy, and surgery
What this could lead to
If successful, this could identify the most effective combination of treatments before surgery to improve survival and reduce cancer recurrence for esophageal cancer patients.
What could go wrong
This is an early-phase study with many different treatment combinations, so results may not show a clear winner. Side effects from chemotherapy, radiation, and immunotherapy can be severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SURGERY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
RECRUITINGBeijing, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••